Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol vwMRI in Intracranial Atherosclerosis
NCT03084523Phase 1Completed
- Sponsor
- Yale University
- Start
- Apr 2017
- Primary completion
- Jun 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ferumoxytol in intracranial atherosclerosis (ICAD), sponsored by Yale University. Primary endpoint: Vessel Wall Enhancement with Gadolinium compared to Vessel Wall Enhancement with Ferumoxytol at 1 year. Started Apr 2017; status: completed.
02
Drugs
ferumoxytol
03
Conditions
intracranial atherosclerosis (ICAD)
Beyond the preview
Go deeper on NCT03084523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03084523.